Skip to main content
. 2019 Dec 1;9(12):2821–2831.

Figure 1.

Figure 1

A. Alterations of TP53, MDM2, and MDM4 genes in the 129 patients with ER+ BC in the Avera cohort: Y-axis represents the absolute number of alterations while the numbers on the individual bars represent the percentage of alterations in an individual gene. B. Alterations in TP53, MDM2, and MDM4 in ER+ breast invasive carcinomas: Oncoprint presents genetic alterations of TP53, MDM2 and MDM4 in ER+ breast invasive carcinomas (TCGA, 2015) in 594 patients/samples (cBioPortal). The types of alterations are presented in the figure. We acknowledge the cBioPortal for Cancer Genomics site (http://cbioportal.org) which provides a Web resource for exploring, visualizing, and analyzing multi-dimensional cancer genomics data. The portal reduces molecular profiling data from cancer tissues and cell lines into readily understandable genetic, epigenetic, gene expression and proteomic events (Gao et al., 2013, Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal, Sci. Signal., 2 April, Vol. 6, Issue 269, p. pl1 [DOI: 10.1126/scisignal.2004088]). We acknowledge the TCGA Research Network for generating TCGA datasets.